EyeBio targets registrational trial after early success of Wnt agonist in retinal diseases
13 Feb 2024
Clinical Study
EyeBio’s tri-specific Wnt agonist antibody improved visual and anatomical measures in a Phase Ib/IIa trial as a monotherapy and in combination with Regeneron’s Eylea, prompting preliminary plans for a potential registrational study in retinal diseases.
The biotech’s lead candidate Restoret is designed to eliminate leakage in vascular eye diseases by activating the Wnt pathway to restore and maintain the blood-retinal barrier. The Phase Ib/IIa AMARONE trial was stopped early due to Restoret’s promising efficacy and safety, CEO David Guyer told Endpoints News in an interview.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.